The Immunotherapy Drugs Market is projected to reach USD 201.52 Billion, growing at a CAGR of 13.5% during the forecast period.
Northbrook, IL -- (SBWIRE) -- 06/14/2019 -- According to a new market research report "Immunotherapy Drugs Market by Type of Drugs (Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha), Therapy Area (Cancer, Autoimmune Diseases, Infectious Diseases), End-User (Hospitals), Region (North America, Asia-Pacific) - Global Forecast to 2021" published by MarketsandMarkets
The report provides a detailed overview of the major drivers, restraints, opportunities, and threat impacting the global Immunotherapy Drugs Market along with the estimates and forecasts of the revenue and market share analysis. Based on the type of drugs, the Immunotherapy Drugs Market is segmented into monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins, and others. Adult vaccines segment is further categorized into preventive vaccines and therapeutic vaccines.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137717755
Furthermore, based on therapy area, the Immunotherapy Drugs Market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and others. Cancer segment is further sub-segmented into solid tumors and malignant tumors. Among these segments, the cancer segment is expected to account for the largest market share in 2016. The large share and high growth of this segment can be attributed to factor such as high preference for immunotherapy as a first line of treatment in cancer leading to growing demand for immunotherapy drugs. The others segment comprises of cardiovascular, and ophthalmic diseases. Based on type of end-users in the healthcare industry, the Immunotherapy Drugs Market is segmented into hospitals, clinics, and others. The others segment comprises of home healthcare centers, and nursing home facilities.
A number of factors such as increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. On the other hand, the high cost of immunotherapy treatment and high attrition rate in the product development cycle are the major factors hindering the growth of the Immunotherapy Drugs Market. However, rising opportunities in the emerging markets and immunotherapy as an alternative to chemotherapy for first line treatment are the factors supporting the growth of Immunotherapy Drugs Market
Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=137717755
North America is expected to account for largest share in the Immunotherapy Drugs Market, by region in 2016. Asia-Pacific is expected to be the fastest-growing regional segment in the Immunotherapy Drugs Market. The high growth of this segment can primarily be attributed to the low cost of manufacturing and acceptable regulatory scenario in this region.
The major players operating in the Immunotherapy Drugs Market include F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline (U.K.), AbbVie, Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.). Bristol-Myers Squibb (U.S.), Novartis International AG (Switzerland), Eli Lilly and Company (U.S.), Johnson & Johnson (U.S.), and AstraZeneca plc (U.K.).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062